Study of SACI-IO for Triple Negative Metastatic Breast Cancer

Name: Study of SACI-IO for Triple Negative Metastatic Breast Cancer
Uploaded: 2021-04-12T00:00:00+00:00
Description: Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute testing the safety and efficacy of sacituzumab govitecan (Trodelvy) with or without pembrolizumab (Keytruda) for patients with PD-L1-negative, triple-negative metastatic breast cancer.

Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute testing the safety and efficacy of sacituzumab govitecan (Trodelvy) with or without pembrolizumab (Keytruda) for patients with PD-L1-negative, triple-negative metastatic breast cancer.

Published

April 12, 2021

Created by

Related Presenters

Filipa Lynce, MD

Medical Oncology

Dr. Lynce received her medical degree from the Universidade Nova de Lisboa, Portugal in 2004.

View Profile